EDOXABAN TOSYLATE Drug Interactions
Also known as: SAVAYSA
Savaysa (edoxaban tosylate) is a type of blood thinner that works by blocking a specific clotting factor in your blood. It is prescribed to reduce the risk of stroke and dangerous blood clots in people with a heart condition called nonvalvular atrial fibrillation. Savaysa is also used to treat existing deep vein clots in the legs (DVT) and blood clots in the lungs (PE) after initial treatment with another medication.EDOXABAN TOSYLATE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with edoxaban greatly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to serious safety concerns.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis. This leads to decreased platelet aggregation and can cause direct gastric mucosal damage. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing thrombin generation and clot formation. The combination results in additive antiplatelet and anticoagulant effects, significantly impairing hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other serious bleeding events. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOACs alone, with GI bleeding being particularly prevalent. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies first. If no alternatives exist, use the lowest effective dose of the NSAID for the shortest possible duration, and closely monitor for signs of bleeding. Proton pump inhibitors (PPIs) should be co-prescribed to reduce GI bleeding risk. Consider alternative analgesics such as acetaminophen.
Combining etodolac (an NSAID) with edoxaban (a blood thinner) significantly increases your risk of bleeding, including serious internal bleeding. You should avoid taking these medications together.
Mechanism
Etodolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing clot formation. The concomitant use of an NSAID and a DOAC results in additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also other sites like intracranial hemorrhage. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2 to 3 times compared to DOACs alone, with GI bleeding being the most common and serious adverse event. Concomitant use of etodolac and edoxaban should generally be avoided due to the high bleeding risk. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely essential, use the lowest effective dose for the shortest possible duration, and monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds). Proton pump inhibitor (PPI) co-therapy may be considered to reduce GI bleeding risk if NSAID use is unavoidable.
Combining aspirin with edoxaban significantly increases your risk of bleeding, including serious internal bleeding. Your doctor will need to carefully weigh the benefits and risks of this combination.
Mechanism
Aspirin inhibits platelet aggregation, primarily by irreversibly acetylating cyclooxygenase-1 (COX-1), which reduces thromboxane A2 production. Edoxaban is a direct oral anticoagulant that selectively inhibits factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This includes minor bleeding (e.g., bruising, nosebleeds, gum bleeding) and major bleeding events such as gastrointestinal hemorrhage, intracranial hemorrhage, or other internal bleeding. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2 to 3-fold compared to DOACs alone, with GI bleeding being particularly common. This combination should generally be avoided due to the high bleeding risk. If concurrent use is deemed absolutely necessary, it should be for the shortest possible duration and with extreme caution, requiring close monitoring for signs of bleeding. Consider alternative pain management strategies that do not increase bleeding risk. Patients should be educated on bleeding symptoms and advised to seek immediate medical attention if they occur.
Combining ibuprofen with edoxaban significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which reduces the protective mucosal barrier in the gastrointestinal tract and impairs platelet function. Edoxaban is a direct oral anticoagulant that inhibits Factor Xa, preventing clot formation. The concurrent use of both agents leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis). The risk of major bleeding can be several-fold higher compared to using either drug alone. Other bleeding events, such as epistaxis, hematuria, or bruising, may also be exacerbated. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (e.g., celecoxib), though this still carries significant risk. Close monitoring for signs of bleeding is crucial, and patients should be educated on symptoms requiring immediate medical attention. Proton pump inhibitors may be considered for gastroprotection if short-term use is unavoidable.
Combining Indomethacin with Edoxaban significantly increases your risk of bleeding, including serious internal bleeding. You should avoid taking these medications together unless specifically directed and closely monitored by your doctor.
Mechanism
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation, which prolongs bleeding time. Edoxaban is a direct oral anticoagulant (DOAC) that directly inhibits factor Xa, preventing thrombin generation and fibrin formation. The concurrent use of these agents results in an additive pharmacodynamic effect, profoundly impairing hemostasis.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal, intracranial, and other major hemorrhages. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2 to 3-fold compared to DOACs alone, with gastrointestinal bleeding being a particular concern. Symptoms can include unusual bruising, nosebleeds, blood in urine or stool, or severe headaches. Concurrent use of Indomethacin and Edoxaban should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternatives with lower systemic absorption (e.g., topical NSAIDs) or alternative pain management strategies. If co-administration is unavoidable, patients require very close monitoring for signs and symptoms of bleeding, and the lowest effective doses for the shortest duration should be used. Proton pump inhibitors may be considered to mitigate gastrointestinal bleeding risk.
Combining celecoxib with edoxaban significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided due to the heightened bleeding risk.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal defense and platelet aggregation, thereby increasing the risk of gastrointestinal bleeding. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or life-threatening. Other bleeding sites may include intracranial hemorrhage, hematuria, or epistaxis. Studies show that combining NSAIDs with anticoagulants can increase GI bleeding risk by 3 to 15 times. This combination should be avoided if possible. If an NSAID is absolutely necessary, consider alternative pain management strategies or a different NSAID with lower systemic absorption (e.g., topical diclofenac) under strict medical supervision. Closely monitor for signs of bleeding (e.g., black/tarry stools, unusual bruising, prolonged bleeding from cuts). Proton pump inhibitor co-therapy may be considered to reduce GI bleeding risk if NSAID use is unavoidable.
Combining piroxicam with edoxaban significantly increases your risk of serious bleeding, including stomach bleeding. You should avoid this combination unless specifically instructed by your doctor, who will weigh the risks carefully.
Mechanism
Piroxicam, a non-selective NSAID, inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, profoundly increasing the risk of hemorrhage.
Clinical Management
This combination carries a substantially elevated risk of major bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other site-specific bleeding. The risk of gastrointestinal bleeding can be 3-15 times higher compared to anticoagulant monotherapy, potentially leading to anemia, hospitalization, or even death. This combination should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a less potent analgesic. If concurrent use is unavoidable, monitor closely for signs of bleeding (e.g., melena, hematemesis, bruising) and consider gastroprotective agents. Discuss with the prescribing physician to assess the risk-benefit and explore alternatives.
Combining meloxicam with edoxaban significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing clot formation. The combined effect leads to an additive increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding, which can manifest as dark stools, vomiting blood, or severe abdominal pain. Studies show a significantly elevated risk of major bleeding events, potentially 2-3 times higher than with either drug alone. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies first. If no alternatives exist, use the lowest effective dose for the shortest possible duration, and monitor closely for signs of bleeding. Proton pump inhibitors may be co-prescribed to reduce GI bleeding risk, but this does not eliminate the overall increased bleeding risk. Reassess the need for both medications.
Combining diclofenac, an anti-inflammatory pain reliever, with edoxaban, a blood thinner, significantly increases your risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, reducing thrombin generation and fibrin clot formation. The concomitant use of an NSAID with an anticoagulant results in an additive antiplatelet and anticoagulant effect, significantly increasing the risk of bleeding.
Clinical Management
Patients are at a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), intracranial hemorrhage, and other serious bleeding events. The risk of major bleeding can be several-fold higher compared to anticoagulant monotherapy, with gastrointestinal bleeding being the most common serious adverse event. Concomitant use of diclofenac and edoxaban should generally be avoided due to the high risk of serious bleeding. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely essential and no other options exist, use the lowest effective dose for the shortest possible duration, and monitor closely for signs of bleeding. Consider gastroprotective agents (e.g., proton pump inhibitors) if NSAID use is unavoidable.
Combining ketorolac with edoxaban significantly increases your risk of bleeding, including serious and life-threatening bleeding episodes, particularly in the stomach and intestines.
Mechanism
Ketorolac, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Edoxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially elevated risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOAC monotherapy, with a particularly high risk of upper gastrointestinal bleeding. This combination should generally be avoided due to the high bleeding risk. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest duration possible, and monitor closely for signs of bleeding. Proton pump inhibitor co-therapy may be considered to reduce GI bleeding risk.
For complete prescribing information:
View full EDOXABAN TOSYLATE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.